129 related articles for article (PubMed ID: 33292132)
1. Targeted biological effect of an affitoxin composed of an HPV16E7 affibody fused with granzyme B (ZHPV16E7-GrB) against cervical cancer in vitro and in vivo.
Wang W; Tan X; Jiang J; Cai Y; Feng F; Zhang L; Li W
Curr Cancer Drug Targets; 2020 Dec; ():. PubMed ID: 33292132
[TBL] [Abstract][Full Text] [Related]
2. A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer.
Jiang P; Wang L; Hou B; Zhu J; Zhou M; Jiang J; Wang L; Chen S; Zhu S; Chen J; Zhang L
Theranostics; 2018; 8(13):3544-3558. PubMed ID: 30026865
[TBL] [Abstract][Full Text] [Related]
3. Bispecific affibody molecule targeting HPV16 and HPV18E7 oncoproteins for enhanced molecular imaging of cervical cancer.
Zhu S; Zhu J; Song Y; Chen J; Wang L; Zhou M; Jiang P; Li W; Xue X; Zhao KN; Zhang L
Appl Microbiol Biotechnol; 2018 Sep; 102(17):7429-7439. PubMed ID: 29938318
[TBL] [Abstract][Full Text] [Related]
4. Significant growth inhibition by a bispecific affibody targeting oncoprotein E7 in both HPV16 and 18 positive cervical cancer in vitro and in vivo.
Tan X; Yang J; Jiang J; Wang W; Ren J; Li Q; Xie Z; Chen X; Zhang L; Li W
Eur J Pharm Sci; 2022 May; 172():106156. PubMed ID: 35245683
[TBL] [Abstract][Full Text] [Related]
5. Generation of affibody molecules specific for HPV16 E7 recognition.
Xue X; Wang B; Du W; Zhang C; Song Y; Cai Y; Cen D; Wang L; Xiong Y; Jiang P; Zhu S; Zhao KN; Zhang L
Oncotarget; 2016 Nov; 7(45):73995-74005. PubMed ID: 27659535
[TBL] [Abstract][Full Text] [Related]
6. A high-risk papillomavirus 18 E7 affibody-enabled in vivo imaging and targeted therapy of cervical cancer.
Wang L; Du W; Zhu S; Jiang P; Zhang L
Appl Microbiol Biotechnol; 2019 Apr; 103(7):3049-3059. PubMed ID: 30770966
[TBL] [Abstract][Full Text] [Related]
7. Novel Affibody Molecules Targeting the HPV16 E6 Oncoprotein Inhibited the Proliferation of Cervical Cancer Cells.
Zhu J; Kamara S; Wang Q; Guo Y; Li Q; Wang L; Chen J; Du Q; Du W; Chen S; Zhu S; Chen J; Chu M; Zhang L
Front Cell Dev Biol; 2021; 9():677867. PubMed ID: 34109181
[TBL] [Abstract][Full Text] [Related]
8. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.
Cheung LH; Zhao Y; Alvarez-Cienfuegos A; Mohamedali KA; Cao YJ; Hittelman WN; Rosenblum MG
J Exp Clin Cancer Res; 2019 Jul; 38(1):332. PubMed ID: 31362764
[TBL] [Abstract][Full Text] [Related]
9. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B.
Alvarez de Cienfuegos A; Cheung LH; Mohamedali KA; Whitsett TG; Winkles JA; Hittelman WN; Rosenblum MG
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958685
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells.
Liu Y; Cheung LH; Thorpe P; Rosenblum MG
Mol Cancer Ther; 2003 Oct; 2(10):949-59. PubMed ID: 14578460
[TBL] [Abstract][Full Text] [Related]
12. Preparation, Characterization and Diagnostic Valuation of Two Novel Anti-HPV16 E7 Oncoprotein Monoclonal Antibodies.
Hu R; Dong Z; Zhang K; Pan G; Li C; Cui H
Viruses; 2020 Mar; 12(3):. PubMed ID: 32204370
[TBL] [Abstract][Full Text] [Related]
13. A recombinant affitoxin derived from a HER3 affibody and diphteria-toxin has potent and selective antitumor activity.
Nazari M; Emamzadeh R; Jahanpanah M; Yazdani E; Radmanesh R
Int J Biol Macromol; 2022 Oct; 219():1122-1134. PubMed ID: 36041577
[TBL] [Abstract][Full Text] [Related]
14. A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors.
Qian X; Shi Z; Qi H; Zhao M; Huang K; Han D; Zhou J; Liu C; Liu Y; Lu Y; Yuan X; Zhao J; Kang C
Theranostics; 2019; 9(25):7616-7627. PubMed ID: 31695790
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Detection of Human Papillomavirus 16 E7 Oncoprotein in Cervical Lesions.
Zhu J; Chen L; Zheng Q; Han R; Chen X; Zhou Q; Cheng H
J Cancer; 2021; 12(23):7130-7137. PubMed ID: 34729114
[TBL] [Abstract][Full Text] [Related]
16. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
[TBL] [Abstract][Full Text] [Related]
17. Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma.
Zhu S; Chen J; Xiong Y; Kamara S; Gu M; Tang W; Chen S; Dong H; Xue X; Zheng ZM; Zhang L
PLoS Pathog; 2020 Jan; 16(1):e1008223. PubMed ID: 31905218
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents.
Liu Y; Cheung LH; Hittelman WN; Rosenblum MG
Mol Cancer Ther; 2003 Dec; 2(12):1341-50. PubMed ID: 14707275
[TBL] [Abstract][Full Text] [Related]
19. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
[TBL] [Abstract][Full Text] [Related]
20. Sustained expression of HPV16 E7 oncoprotein promotes p-AKT(Ser473)/p-Src(Tyr527) signaling to drive precancerous lesions to invasive cervical cancer.
Lin Z; Zhao Y; Li Q; Ci X; Ye X; Chen G; Tu Q; Feng W; Jiang P; Zhu S; Xue X; Saunders NA; Zhang L; Zhu X; Zhao KN
Carcinogenesis; 2022 Jun; 43(5):479-493. PubMed ID: 35134836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
